Also, investigations of PSA serum from 40 patients revealed an increase in the glycans containing Fucα1,2Galβ1,4GlcNAc and GalNAcβ1,4GlcNAc for patients with prostate cancer as opposed to those with benign prostatic hyperplasia (BPH) [31]. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.